← Back to Search

Thyroid hormone receptor agonist

MGL-3196 for Non-alcoholic Fatty Liver Disease

Phase 2
Waitlist Available
Research Sponsored by Madrigal Pharmaceuticals, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 and 36 weeks
Awards & highlights

Study Summary

The primary objective of this study is to determine the effect of once-daily oral MGL-3196 on the percent change in hepatic fat fraction from baseline in patients with biopsy-proven Non-alcoholic Steatohepatitis (NASH).

Eligible Conditions
  • Non-alcoholic Fatty Liver Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 and 36 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 and 36 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change from baseline in hepatic fat fraction assessed by MRI-PDFF
Secondary outcome measures
Change from baseline in hepatic fat fraction
Effect on NASH and fibrosis biomarkers
Aspartate Transaminase
+7 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: MGL-3196Experimental Treatment1 Intervention
Study Drug
Group II: PlaceboPlacebo Group1 Intervention
Matching Placebo
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
MGL-3196
Not yet FDA approved

Find a Location

Who is running the clinical trial?

Madrigal Pharmaceuticals, Inc.Lead Sponsor
14 Previous Clinical Trials
5,465 Total Patients Enrolled
4 Trials studying Non-alcoholic Fatty Liver Disease
4,430 Patients Enrolled for Non-alcoholic Fatty Liver Disease

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Hepatology CommunicationsJournal
Effects of Resmetirom on Noninvasive Endpoints in a 36‐week Phase 2 Active Treatment Extension Study in Patients with <scp>nash</scp>
Harrison, Stephen A., Mustafa Bashir, Sam E. Moussa, Kevin McCarty, Juan Pablo Frias, Rebecca Taub, and Naim Alkhouri. 2021. “Effects of Resmetirom on Noninvasive Endpoints in a 36‐week Phase 2 Active Treatment Extension Study in Patients with nash”. Hepatology Communications. Wiley. doi:10.1002/hep4.1657.
clinicaltrials.govStudy
Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH)
2016. "Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02912260.
All > Autoimmune Hepatitis > Nash
~15 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top